Peter Bross

Prof. Peter Bross

Research Unit for Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JHJens Jacob Hansen
Jens Jacob Hansen
ADAlexandra Dürr
Alexandra Dürr
ICIsabelle Cournu-Rebeix
Isabelle Cournu-Rebeix
CGCosta Georgopoulos
Costa Georgopoulos
DADebbie Ang
Debbie Ang
Peter BrossPeter Bross
Peter Bross

15 May 1999 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Jens MogensenJens Mogensen
Jens Mogensen
IKIb C. Klausen
Ib C. Klausen
APAnders K. Pedersen
Anders K. Pedersen
HEHenrik Egeblad
Henrik Egeblad
Peter BrossPeter Bross
Peter Bross
ABAnders D. Børglum
Anders D. Børglum
We identified the α-cardiac actin gene (ACTC) as a novel disease gene in a pedigree suffering from familial hypertrophic cardiomyopathy (FHC). Linkage analyses excluded all the previously reported FHC loci as possible disease loci in the family studied, with lod scores varying between –2.5 and –6.0. Further linkage analyses of plausible candidate genes highly expressed in the adult human heart identified ACTC as the most likely disease gene, showing a maximal lod score of 3.6. Mutation analysis of ACTC revealed an Ala295Ser mutation in exon 5 close to 2 missense mutations recently described to cause the inherited form of idiopathic dilated cardiomyopathy (IDC). ACTC is the first sarcomeric gene described in which mutations are responsible for 2 different cardiomyopathies. We hypothesize that ACTC mutations affecting sarcomere contraction lead to FHC and that mutations affecting force transmission from the sarcomere to the surrounding syncytium lead to IDC.

1 February 1999 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BABrage Storstein Andresen
Brage Storstein Andresen
SOSimon Olpin
Simon Olpin
BPBen J.H.M. Poorthuis
Ben J.H.M. Poorthuis
HSHans R. Scholte
Hans R. Scholte
CVChristine Vianey-Saban
Christine Vianey-Saban
NGNiels Gregersen
Niels Gregersen

1 September 2006 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Closed access
NGNiels Gregersen
Niels Gregersen
Peter BrossPeter Bross
Peter Bross
SVSøren Vang
Søren Vang
JCJane H. Christensen
Jane H. Christensen
Protein misfolding is a common event in living cells. In young and healthy cells, the misfolded protein load is disposed of by protein quality control (PQC) systems. In aging cells and in cells from certain individuals with genetic diseases, the load may overwhelm the PQC capacity, resulting in accumulation of misfolded proteins. Dependent on the properties of the protein and the efficiency of the PQC systems, the accumulated protein may be degraded or assembled into toxic oligomers and aggregates. To illustrate this concept, we discuss a number of very different protein misfolding diseases including phenylketonuria, Parkinson's disease, α-1-antitrypsin deficiency, familial neurohypophyseal diabetes insipidus, and short-chain acyl-CoA dehydrogenase deficiency. Despite the differences, an emerging paradigm suggests that the cellular effects of protein misfolding provide a common framework that may contribute to the elucidation of the cell pathology and guide intervention and treatment strategies of many genetic and age-dependent diseases.

1 June 2001 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BABrage Storstein Andresen
Brage Storstein Andresen
SDSteve F. Dobrowolski
Steve F. Dobrowolski
LOLinda O'REilly
Linda O'REilly
JMJoseph Muenzer
Joseph Muenzer
SMShawn E. McCandless
Shawn E. McCandless
NGNiels Gregersen
Niels Gregersen

13 June 2003 in Human Mutation
Verified
Journal Article
Closed access
PDF file
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
BABrage Storstein Andresen
Brage Storstein Andresen
ECErnst Christensen
Ernst Christensen
Peter BrossPeter Bross
Peter Bross
FSFlemming Skovby
Flemming Skovby
NGNiels Gregersen
Niels Gregersen
Mutations in electron transfer flavoprotein (ETF) and its dehydrogenase (ETFDH) are the molecular basis of multiple acyl-CoA dehydrogenation deficiency (MADD), an autosomal recessively inherited and clinically heterogeneous disease that has been divided into three clinical forms: a neonatal-onset form with congenital anomalies (type I), a neonatal-onset form without congenital anomalies (type II), and a late-onset form (type III). To examine whether these different clinical forms could be explained by different ETF/ETFDH mutations that result in different levels of residual ETF/ETFDH enzyme activity, we have investigated the molecular genetic basis for disease development in nine patients representing the phenotypic spectrum of MADD. We report the genomic structures of the ETFA, ETFB, and ETFDH genes and the identification and characterization of seven novel and three previously reported disease-causing mutations. Our molecular genetic investigations of these nine patients are consistent with three clinical forms of MADD showing a clear relationship between the nature of the mutations and the severity of disease. Interestingly, our data suggest that homozygosity for two null mutations causes fetal development of congenital anomalies resulting in a type I disease phenotype. Even minute amounts of residual ETF/ETFDH activity seem to be sufficient to prevent embryonic development of congenital anomalies giving rise to type II disease. Overexpression studies of an ETFB-D128N missense mutation identified in a patient with type III disease showed that the residual activity of the mutant enzyme could be rescued up to 59% of that of wild-type activity when ETFB-D128N-transformed E. coli cells were grown at low temperature. This indicates that the effect of the ETF/ETFDH genotype in patients with milder forms of MADD, in whom residual enzyme activity allows modulation of the enzymatic phenotype, may be influenced by environmental factors like cellular temperature. Hum Mutat 22:12–23, 2003.